ALLERGAN AUSTRALIA PTY LIMITED

BostonSight published a study in *Clinical Ophthalmology* on using PROSE (scleral lenses) as a drug delivery device for preservative-free Cyclosporine 0.05% to treat dry eye disease, reporting encouraging results in symptom relief and ocular surface tolerability.

Dr. Rubinstein to train practitioners on new BOTOX® technique for neck contours in New York. BOTOX® Cosmetic received FDA approval for treating platysma bands, expanding its aesthetic applications.

Dr. Ran Y. Rubinstein selected to train professionals on FDA-approved BOTOX® Cosmetic for platysma bands in Montvale, NJ, enhancing skills in non-surgical neck rejuvenation.

Cybin's CYB003, a deuterated psilocin drug for MDD, showed 12-month efficacy with 100% response rate and 71% sustained remission. The FDA's Breakthrough Therapy Designation supports its potential over existing therapies, with no new adverse events reported. Cybin plans to launch Phase 3 PARADIGM program for global efficacy and safety assessment.

The Global Acute Migraine Drugs Market is projected to grow at a CAGR of 8.58% from 2023 to 2030, reaching USD 8.75 Billion by 2030, driven by increasing migraine prevalence, pharmaceutical advancements, and demand for fast-acting treatments.

Emerging therapies like LNZ100, Phentolamine Ophthalmic Solution 0.75%, and BRIMOCHOL PF are set to impact the presbyopia market (2024–2034). Presbyopia, an age-related condition affecting near vision, has ~325 million prevalent cases in 7MM, expected to grow at 1.1% CAGR. Treatments include corrective lenses, surgical procedures, and eye drops like VUITY and QLOSI. Market size is projected to reach ~USD 17 billion by 2034 with a 3.2% CAGR, driven by innovative therapies and rising incidence.

Jasmina Jankicevic discusses how emerging technologies like blockchain, IoT, and AI are transforming clinical trials, emphasizing the importance of real-world evidence and patient-reported outcomes. She predicts decentralized trials will shift CRO roles to more technology-focused services, with AI and machine learning influencing the division of responsibilities between sponsors and CROs. The trend toward precision medicine will lead smaller biotech firms to seek specialized CRO partnerships.

Andrew Pucker's analysis of US clinical trials, presented at the 2024 American Academy of Optometry meeting, provides benchmarks for enrollment, site requirements, and study duration in ophthalmic trials, highlighting Alcon and Allergan as leading sponsors. This data aids researchers in forecasting resources and improving trial success.

A form includes dropdowns for selecting a state, zip code, and country, with California pre-selected as the state and the United States as the country.

Conflicting interpretations on breast implant safety highlight FDA's commitment to transparency and stakeholder engagement, despite challenges in post-market surveillance and data quality. The FDA's reputation is both strengthened and challenged by these conflicts, necessitating robust information-gathering mechanisms to manage public health risks and maintain credibility.